Search results
Showing 16 to 21 of 21 results for denosumab
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
This guidance has been updated and replaced by NICE guideline CG175.
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Bisphosphonates and denosumab to treat osteoporosis:- What is the clinical and cost effectiveness of standard care with bisphosphonates...
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
Thousands of people set to benefit from first new treatment for osteoporosis for over a decade
Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment – romosozumab – after NICE recommended it for people after menopause in final draft guidance published today (Friday 1 April) by NICE.